Predicting disease activity in patients with multiple sclerosis: An explainable machine-learning approach in the Mavenclad trials.

Basu, Sreetama; Munafo, Alain; Ben-Amor, Ali-Frederic; Roy, Sanjeev; Girard, Pascal; Terranova, Nadia

Basu, Sreetama; Munafo, Alain; Ben-Amor, Ali-Frederic; Roy, Sanjeev; Girard, Pascal; Terranova, Nadia.

Afiliación

Basu S; Merck Institute for Pharmacometrics, Merck Serono S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland.
Munafo A; Merck Institute for Pharmacometrics, Merck Serono S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland.
Ben-Amor AF; Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland.
Roy S; Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland.
Girard P; Merck Institute for Pharmacometrics, Merck Serono S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland.
Terranova N; Merck Institute for Pharmacometrics, Merck Serono S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland.

CPT Pharmacometrics Syst Pharmacol ; 11(7): 843-853, 2022 07.

Article en En | MEDLINE | ID: mdl-35521742

Asunto(s)

Esclerosis Múltiple Recurrente-Remitente; Esclerosis Múltiple; Cladribina/uso terapéutico; Humanos; Inmunosupresores/uso terapéutico; Aprendizaje Automático; Esclerosis Múltiple/tratamiento farmacológico; Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico; Adulto Joven

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: CPT Pharmacometrics Syst Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google